Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.

Recent clinical studies have suggested that the combination of subcutaneous recombinant human interleukin 2 (rIL-2) and interferon alpha (rIFN-alpha) is especially promising in advanced renal cell carcinoma. We assessed the safety, activity and toxicity of home therapy with these two agents in 50 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Facendola, G., Locatelli, M. C., Pizzocaro, G., Piva, L., Pegoraro, C., Pallavicini, E. B., Signaroldi, A., Meregalli, M., Lombardi, F., Beretta, G. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034091/
https://www.ncbi.nlm.nih.gov/pubmed/8519672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034091/
https://www.ncbi.nlm.nih.gov/pubmed/8519672

Ejemplares similares